吴闯;姜在龙;金炜;李盈;钱进;王芳;王振宜;

• 1:上海中医药大学附属岳阳中西医结合医院肛肠科
• 2:浙江中医药大学第二附属医院肛肠科

摘要(Abstract)：

目的:研究中医经验方"溃结2号方"对实验性大鼠溃疡性结肠炎(ulcerative colitis,UC)结肠黏膜组织白细胞介素-1β(interleukin-1βIL-1β)、白细胞介素-10(interleukin-10 IL-10)表达的影响。方法:采用2,4,6-三硝基苯磺酸(2,4,6-trinitrobenzene sulfonic acid TNBS)加免疫诱导法复制UC大鼠模型,造模成功后,共36只大鼠,随机分组为模型组,模型+阳性对照组(中药方组),模型+阴性对照组[柳氮磺胺吡啶(SalicylazosulfapyridineSASP)组]大鼠,每组12只。观察大鼠治疗后14 d及21 d后大鼠结肠组织黏膜的病理改变(DAI及CMDI评分结果),用免疫组织化学PAP二步法检测大鼠结肠组织中IL-1β、IL-10的表达。结果:治疗14 d时,实验结果表明:中药组大鼠疾病活动指数(Disease Activity Index DAI)及结肠黏膜损伤指数(ColonicMucosa Damage Index CM-DI)积分明显低于模型组(P<0.05)和SASP组(P<0.05),但与SASP组相比无明显差别;而中药组溃疡创面中IL-1β表达明显低于模型组(P<0.01),也明显低于SASP组(P<0.05);中药组创面中IL-10水平却明显高于模型组与SASP组(P<0.05);治疗21 d时,实验结果显示:中药组大鼠DAI及CMDI积分明显低于模型组(P<0.01)和SASP组(P<0.05),中药组大鼠IL-1β表达明显低于模型组(P<0.01),也明显低于SASP组(P<0.05);中药组IL-10表达明显高于模型组和SASP组(P<0.05)。结论:溃结2号方对溃疡性结肠炎大鼠有良好的治疗作用,且时间越长效果越好,其作用机理可能与降低IL-1β表达,和提高IL-10水平有关。

关键词(KeyWords)： 祛瘀生新法;溃结2号方;溃疡性结肠炎;大鼠;IL-1β;IL-10

Abstract:

Keywords:

基金项目(Foundation): 上海市教委创新课题项目资助(编号:09YZ127)

作者(Author): 吴闯;姜在龙;金炜;李盈;钱进;王芳;王振宜;

Email:

DOI: 10.13463/j.cnki.jlzyy.2012.05.044

参考文献(References)：

• [1]Jun Yun,Chang-Tai Xu,Bo-Rong Pan.Epidemiology and genemarkers of ulcerative colitis in the Chinese[J].World J Gastroen-terol,2009,15(7):788-803.
• [2]Bamias G,Kaltsa G,Ladas SD.Cytokines in the pathogenesis ofulcerative colitis[J].Discov Med,2011,11(60):459-67.
• [3]Anand AC,Adya CM.Cytokines and inflammatory bowel disease[J].Trop Gastroenterol,1999,20(3):97-106.
• [4]Cominelli F,Pizarro T.Interleukin-1 and interleukin-1 receptorantagonist in inflammatory bowel disease[J].Aliment PharmacolTher,1996,10(2):49-53.
• [5]闫伟,潘一滨,陆金根.溃疡性结肠炎的中医药治疗特色与优势[J].辽宁中医药大学学报,2010,12(12):136-138.
• [6]段征,汪维伟,姜蓉.两种溃疡性结肠炎大鼠模型的比较[J].重庆医科大学学报,2008,33(1):66-72.
• [7]黄继汉,黄晓晖,陈志扬,等.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学,2004,9(9):1069-107.
• [8]Bamias G,Kaltsa G,Ladas SD.Cytokines in the pathogenesis ofulcerative colitis[J].Discov Med,2011,11(60):459-67.
• [9]Yan J,Zhang H,Chen CT,et al.Effects of electroacupuncture atShangjuxu(ST37)on interleukin-1beta?and interleukin-4 in theulcerative colitis model rats[J].J Tradit Chin Med,2009,29(1):60-63.
• [10]Ksiadzyna D,Semianow-Wejchert J,Nawrot U,et al.Serum con-centration of interleukin 10,ant-i mannan Candida antibodies andthe fungal colonization ofthe gastrointestinal tract in patients withulcerative colitis[J].Adv Med Sci,2009,54(2):170-6.
• [11]口锁堂,吴焕淦,施达仁.白介素与溃疡性结肠炎[J].世界华人消化杂志,2006,14(4):405-411.
• [12]Rugtveit J,Nilsen EM,Bakka A,et al,Brandtzaeg P,Scott H.Cytokine profiles differ in newly recruited and resident subsets ofmucosal macrophages from inflammatory bowel disease[J].Gas-troenterology,1997,112(5):1493-505.
• [13]NemetzA,KopeA,MolnarT,et al.Significant differences in theinterleukin-beta and interleukin-1 receptor antagonist gene poly-morphisms in a Hungarian population with inflammatory boweldisease[J].Scand J Gastroenterol,1999,34(2):175-179.
• [14]Vermeire S,Van Assche G,Rutgeerts P.The role of C-reactiveprotein as an inflammatory marker in gastrointestinal diseases[J].Nat Clin Pract Gastroenterol Hepatol,2005,2(12):580-586.
• [15]Cao W,Vrees MD,Potanti FM,et al.Interleukin lbeta~inducedproduction ofH202 contributes to reduced sign~id colonic cir-cular smooth muscle contractility in ulcerative colitis[J].Journalof Pharmacology&Experimental Therapeutics,2004,311(1):60-70.
• [16]Borish L.IL-10:evolving concepts[J].J Allergy Clin Immunol,1998,101(3):293-297.
• [17]Rermick DM,Fort MM.Lessons from genetically engineered an-imalmodels.XII.IL-10-deficient(IL-10(-/-)mice and intestinalinflammation[J].Physiol Gastrointest Liver Physiol,2000,278:829-833.
• [18]Matteo Bosani,Sandro Ardizzone,Gabriele Bianchi Porro.Biolog-ic targeting in the treatment of inflammatory bowel diseases[J].Biologics,2009,3:7-97.
• [19]Szkaradkiewicz A,Marciniak R,Chudzicka-Struga aI,et al.Proinflammatory cytokines and IL-10 in inflammatory bowel dis-ease and colorectal cancer patients[J].Arch Immunol Ther Exp(Warsz),2009,57(4):291-4.
• [20]秦震声,王软,赵耀,等.舒肝健脾颗粒对溃疡性结肠炎大鼠模型VIP和IL-10水平的影响[J].吉林中医药,2007,27(3):48-50.
• [21]蔡旭兵,潘立群.黄芪在促血管再生中的应用[J].吉林中医药,2009,29(9):807-808.
• [22]高妮娜,李丽.黄芪调节免疫功能的应用研究[J].长春中医药大学学报,2008,24(6):671.